Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/60818
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuthipun Jitpimolmarden_US
dc.contributor.authorKittisak Sawanyawisuthen_US
dc.contributor.authorNimit Morakoteen_US
dc.contributor.authorAthasit Vejjajivaen_US
dc.contributor.authorMontien Puntumetakulen_US
dc.contributor.authorKanokwan Sanchaisuriyaen_US
dc.contributor.authorWongwiwat Tassaneeyakulen_US
dc.contributor.authorWichittra Tassaneeyakulen_US
dc.contributor.authorNarumanas Korwanichen_US
dc.date.accessioned2018-09-10T03:59:58Z-
dc.date.available2018-09-10T03:59:58Z-
dc.date.issued2007-05-01en_US
dc.identifier.issn09320113en_US
dc.identifier.other2-s2.0-33947363840en_US
dc.identifier.other10.1007/s00436-006-0405-7en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33947363840&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/60818-
dc.description.abstractEosinophilic meningitis in humans is commonly caused by the nematode Angiostrongylus cantonensis. A severe headache is the most common presenting symptom. A prospective, randomized, double-blind, placebo, controlled study was conducted to determine if albendazole was efficacious in relieving such headaches. Seventy-one patients (36 and 35 in the treatment and control groups) were enrolled in the study. Five patients (two and three in the treatment and control groups) were excluded from the study because of being lost to follow-up, and the clinical data were incomplete. Therefore, 34 and 32 patients in the treatment and control groups were studied, respectively. Albendazole was administered at 15 mg/kg/day or identical placebo for 2 weeks. The number of patients with persistent headaches after 2 weeks was 7 and 13 in the albendazole and placebo groups (p=0.08), respectively. The mean duration of a headache was 8.9 and 16.2 days in the albendazole and placebo groups, respectively (p=0.05). No serious drug events were observed. A 2-week course of albendazole appeared to reduce the duration of headache in eosinophilic meningitis. © 2006 Springer-Verlag.en_US
dc.subjectAgricultural and Biological Sciencesen_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.subjectVeterinaryen_US
dc.titleAlbendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensisen_US
dc.typeJournalen_US
article.title.sourcetitleParasitology Researchen_US
article.volume100en_US
article.stream.affiliationsKhon Kaen Universityen_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsMahidol Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.